Advertisement

Picture EBD Group BIO-Europe 2018 Copenhagen Denmark Partnerships 600x60px
Document › Details

Grifols S.A.. (5/10/18). "Press Release: Grifols Reaches an Agreement with Boya Bio-Pharmaceutical to Open Plasma Collection Centers in China". Barcelona.

Region Region China
Organisations Organisation Grifols S.A.
  Group Grifols (Group)
  Organisation 2 Boya Bio-Pharmaceutical (SHE: CN: 300294)
Products Product plasma protein (human)
  Product 2 blood plasma
     


Grifols reinforces its long-term strategy to expand and diversify its access to plasma


> Boya Bio-Pharmaceutical is the leading producer of plasma-derived medicines in China. The agreement includes the construction and management of a significant number of plasma collection centers in China.

> All of the centers will meet Grifols’ strict quality control standards, as well as the criteria established by the health authorities of China, the United States and the European Union.

> The initial investment for the project is Euros 50 million.

> The plasma collected from these centers will be supplied to Boya BioPharmaceutical, although Grifols will be able to access up to 50% of this plasma when the applicable Chinese legislation allows.

> This long-term project supports Grifols’ corporate strategy of expanding and diversifying its network of plasma collection centers to guarantee the future supply of its main raw material

> Grifols continues its investment plans to open new centers. The group leads the industry in plasma collection centers, with 190 centers in the U.S. and 35 in Europe1.


Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the top three global producers of plasma-derived medicines used in the treatment of rare and chronic diseases, and Boya Bio-Pharmaceutical (SHE: CN: 300294), a leading Chinese company specialized in the production of plasma-derived products, have entered into a Master Shareholders Agreement (MSA) for the construction and management of a significant number of plasma collection centers in the People’s Republic of China (PRC).

Under the agreement, the plasma collection centers will be built and managed in adherence to the criteria established by the health authorities of the United States (U.S. Food and Drug Administration), the European Union (European Medicines Agency) and China (China Food and Drug Administration and National Health and Family Planning Commission), among others.

The agreement furthermore includes an Engineering and Collaboration Services Agreement on the part of Grifols, which will bring its experience and know-how to build and manage the plasma collection centers, ensuring the same high standards of quality as in all of the centers that Grifols operates.

The initial investment to implement the project amounts to EUR 50 million and Grifols will control 50% of the decision-making and economic rights of the project.

In accordance with the applicable Chinese legislation, all of the plasma obtained in these centers will be supplied to Boya Bio-Pharmaceutical, although Grifols reserves the right to access 50% of the collected plasma when the applicable legislation allows.

The project will enable Grifols to reinforce its long-term strategy of increasing its access to plasma through geographic diversification to meet the increasing demand for plasma-derived therapies.

Currently, Grifols leads the industry in plasma collection centers, with 190 centers in the U.S. and 35 in Europe1, a 50% increase from the start of the expansion plan in 2015. The group continues its investment plans to open new centers.

In 2017, Grifols obtained more than 9 million liters of plasma to produce its broad portfolio of plasma-derived medicines, which it markets in over 100 countries. Among the main plasma proteins used for therapeutic purposes are immunoglobulins, to treat immunological disorders, including certain neurological diseases; albumin, to restore and maintain circulatory volume, as well as to treat liver diseases; factor VIII, for the treatment and prophylaxis of hemophilia; and alpha-1 antitrypsin, to protect against lung tissue damage (pulmonary emphysema).

Grifols Corporate Responsibility Reports include detailed information on plasma, plasma donors and management of the value chain in the production of plasmaderived therapies. This document is available on Grifols’ corporate website at www.grifols.com


----------------------------

1 Acquisition of European centers subject to approval by the German Competition Authority.

----------------------------


Investors’ contact:

Investor Relations Department
inversores@grifols.com - investors@grifols.com
Phone number: +34 93 571 02 21

Media contact:

Raquel Lumbreras
raquel_lumbreras@duomocomunicacion.com
Borja Gómez
borja_gomez@duomocomunicacion.com
Duomo Comunicación - Grifols Press Office
Phone number:
+34 91 311 92 89 - +34 91 311 92 90


About Grifols

Grifols is a global healthcare company with more than 75 years of legacy dedicated to improving the health and well-being of people around the world. Grifols produces essential plasma-derived medicines for patients and provides hospitals and healthcare professionals with the tools, information and services they need to help them deliver expert medical care.

Grifols’ three main divisions - Bioscience, Diagnostic and Hospital - develop, produce and market innovative products and services that are available in more than 100 countries.

With a network of more than 190 plasma collection centers, Grifols is a leading producer of plasma-derived medicines used to treat rare, chronic and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols offers a comprehensive portfolio of diagnostic products designed to support safety from donation through transfusion. The Hospital Division provides intravenous (IV) therapies, clinical nutrition products and hospital pharmacy systems, including systems that automate drug compounding and control drug inventory.

Grifols is headquartered in Barcelona, Spain and has 18,300 employees in 30 countries.

In 2017, sales exceeded 4,300 million euros. Grifols demonstrates its strong commitment to advancing healthcare by allocating a significant portion of its annual income to research, development and innovation.
The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the US NASDAQ via ADRs (NASDAQ:GRFS).

For more information, visit www.grifols.com


LEGAL DISCLAIMER

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.

   
Record changed: 2018-05-16

Advertisement

Picture [LSUK] Life-Sciences-UK.com – The Business Web Portal 600x80px

More documents for Grifols (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2018 Boston Speakers 600x60px




» top